Related Experiment Videos
Malignant adrenal tumors
1Section of Pediatric Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202-5200, USA. frescorl@iupui.edu
Seminars in Pediatric Surgery
|February 7, 2006
Summary
Pediatric adrenal tumors are rare, often hormonally active, and challenging to diagnose preoperatively. Surgical excision is key, with approach tailored to tumor invasiveness and spread.
Area of Science:
- Pediatric Endocrinology
- Pediatric Oncology
- Surgical Oncology
Background:
- Adrenal tumors, excluding neuroblastoma, are uncommon in pediatric patients.
- Distinguishing benign from malignant adrenal lesions is difficult due to hormonal activity and overlapping features.
- Adrenocortical carcinoma and pheochromocytoma are the primary malignant adrenal tumors in children.
Purpose of the Study:
- To review the diagnostic challenges and management strategies for pediatric adrenal tumors.
- To highlight the importance of accurate preoperative diagnosis for guiding treatment.
- To discuss surgical approaches and the role of chemotherapy in managing these rare tumors.
Main Methods:
- Review of literature on pediatric adrenal tumors.
- Analysis of diagnostic difficulties, including hormonal activity and imaging interpretation.
- Evaluation of surgical techniques (open vs. laparoscopic) based on tumor characteristics.
- Assessment of chemotherapy's role in unresectable or metastatic disease.
Main Results:
- Accurate preoperative diagnosis of pediatric adrenal tumors is often challenging.
- Both benign and malignant tumors can exhibit hormonal activity.
- Surgical excision is the mainstay of treatment for adrenal tumors, including metastatic and recurrent cases.
- Surgical approach (open or laparoscopic) depends on tumor invasiveness and metastatic potential.
Conclusions:
- Pediatric adrenal tumors require careful preoperative evaluation due to diagnostic complexities.
- Surgical management should be individualized based on tumor type, stage, and invasiveness.
- The role of chemotherapy remains limited, particularly in the absence of proven efficacy for metastatic or unresectable pediatric adrenal tumors.